Topical antibiotic/antimicrobial combination (Duac®); Topical retinoid (Differin®)

This page covers all Topical antibiotic/antimicrobial combination (Duac®); Topical retinoid (Differin®) drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Bacterial ribosome (clindamycin); Retinoic acid receptor (adapalene); Reactive oxygen species generation (benzoyl peroxide), retinoic acid receptor, sebaceous glands.

Targets

Bacterial ribosome (clindamycin); Retinoic acid receptor (adapalene); Reactive oxygen species generation (benzoyl peroxide) · retinoic acid receptor · sebaceous glands

Marketed (1)

• Duac® Gel / Differin® Gel · Stiefel, a GSK Company · Dermatology
  Duac® Gel combines clindamycin (an antibiotic) and benzoyl peroxide (an antimicrobial oxidizing agent) to reduce acne-causing bacteria and inflammation, while Differin® Gel contains adapalene (a retinoid) that normalizes skin cell turnover and reduces comedone formation.

Phase 3 pipeline (3)

• QM1114-DP · Galderma R&D · Dermatology
  QM1114-DP is a topical treatment that targets the inflammatory pathways in the skin.
• S6G5T-3 · Sol-Gel Technologies, Ltd. · Dermatology
  S6G5T-3 is a topical gel formulation of a proprietary molecule that targets the sebaceous glands to treat acne.
• Product 55394 · Medicis Global Service Corporation · Dermatology
  Product 55394 is a topical gel used to treat moderate to severe acne.

Phase 2 pipeline (1)

• CD10367 3% Solution - Non-desquamated zone · Galderma R&D · Dermatology
  CD10367 3% Solution - Non-desquamated zone is a topical treatment for acne.

Patent intelligence

• topical retinoid patent landscape — aggregated cliff calendar, attackable patents, originator estates